Patent classifications
G01N33/56916
METHOD OF DETECTING AN ANALYTE USING CHROMATOGRAPHIC ENRICHMENT
A device is provided. The device comprises a casing comprising an interior, a first opening, and a second opening; and a porous carrier comprising a sample-receiving zone and a target analyte-binding zone. The porous carrier defines a first fluid pathway that extends from the sample-receiving zone to the target analyte-binding zone. At least portion of the porous carrier is disposed in the interior of the casing. A second fluid pathway comprising a central axis extends through the casing from the first opening and the second opening, the second fluid pathway intersecting the porous carrier at the target analyte-binding zone. The central axis is oriented orthogonally with respect to the porous carrier. Methods of using the device to detect a target analyte are also provided.
System and Method for Pathogen Detection Using Multiple-Sized Polymer-Coated Beads within Lyotropic Chromonic Liquid Crystals
A novel detection system and method is presented, where a two-bead receptor method is used for capturing pathogens, with one type of bead being magnetic and having a size of 3 microns or smaller, and the other type being polymeric and having a size of 3 microns or larger. The first type is used to concentrate a pathogen; the latter is used to create a detectable signal. Fast sensitive detection is achieved by collecting the optical signal created by the distortion of a homeotropically aligned chromonic azo dye in the presence of captured pathogens.
Primers for detecting serotypes of Shigella flexneri and multiplex amplifications using the same
The present inventions relates to primers for identifying Shigella flexneri serotypes comprising the sequences of SEQ ID Nos. 1 and 2, SEQ ID Nos. 3 and 4, SEQ ID Nos. 5 and 6, SEQ ID Nos. 7 and 8, SEQ ID Nos. 9 and 10, SEQ ID Nos. 11 and 12, SEQ ID Nos. 13 and 14, SEQ ID Nos. 15 and 16. These primers are specific and have a common annealing temperature. The present invention further relates to a multiplex amplification-based identification method using the primers. The present invention further relates to the use of the primers for identifying Shigella flexneri serotypes for the preparation of identification agents. The present invention further relates to a kit for identifying Shigella flexneri comprising the above primers.
Method for increasing ETEC CS6 antigen presentation on cell surface and products obtainable thereof
A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETC. Cells and vaccines obtainable by the above methods.
Assays for antimicrobial activity and applications thereof
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Method for treating at least one biological sample containing a target microorganism
One embodiment provides a device for processing at least one biological sample capable of containing at least one target microorganism within at least one container. The device having at least one displacement device for generating the displacement of the contents of the at least one container and at least one site for receiving the at least one container. Additionally, the at least one container can receive the at least one biological sample within the at least one container, the container being delimited by a wall fixed on a base. Further, the at least one displacement device may be movable with respect to the base, and the at least one container may include a flexible material which allows the at least one container to be compressed against said wall.
System and Method for Integration of Mobile Device Imaging with Microchip Elisa
A system and method for analyzing a biomarker in a biological sample is provided. A biological sample is loaded onto a microchip and an enzyme-linked immunosorbent assay specific to the biomarker is performed on the microchip. A color image of the microchip is generated using a mobile device and a color intensity of a selected portion of the color image is determined. The color intensity is correlated with a biomarker concentration using a baseline curve calculation and the concentration of the biomarker is then reported.
Companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant
The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's GI tract, specifically the GI tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in GI tract samples, e.g. by nucleic acid analysis.
REAL-TIME DETECTION OF WATER CONTAMINANTS
Provided herein is a field-effect transistor based sensor for real-time detection of water contaminants and methods of use thereof.
Methods and Compositions for Treating Ulcerative Colitis
The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.